**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 88459

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival**

Leung PY *et al.* Erlotinib combined with MitoQ suppresses PDAC

Pui-Yin Leung, Wenjing Chen, Anissa N Sari, Poojitha Sitaram, Pui-Kei Wu, Susan Tsai, Jong-In Park

**Pui-Yin Leung, Wenjing Chen, Anissa N Sari, Pui-Kei Wu, Jong-In Park,** Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, United States

**Poojitha Sitaram, Susan Tsai,** Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, United States

**Co-first authors:** Pui-Yin Leung and Wenjing Chen.

**Author contributions:** Leung PY designed and performed research, and analyzed data; Chen W designed and performed research, analyzed data, and wrote the paper; Sari AN performed research and analyzed data; Wu PK developed methodology; Sitaram P performed research and analyzed data; Tsai S secured funding for this study; Park JI conceived and designed research, wrote the paper, secured funding, and supervised the project. All authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. Leung PY and Chen W contributed equally to this work as co-first authors. Designating these two authors as co-first authors accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper.

**Supported by** NIH/National Cancer Institute Grant, No. R01CA138441 and No. R01CA269452; UW Madison Centene Pancreas Cancer Collaborative Award, No. 21-8568.

**Corresponding author: Jong-In Park, PhD, Professor,** Department of Biochemistry, Medical College of Wisconsin, No. 8701 Watertown Plank Road, Milwaukee, WI 53226, United States. jipark@mcw.edu

**Received:** September 26, 2023

**Revised:** December 13, 2023

**Accepted:** January 17, 2024

**Published online:**

**Abstract**

BACKGROUND

Pancreatic cancer is a leading cause of cancer-related deaths. Increased activity of the epidermal growth factor receptor (EGFR) is often observed in pancreatic cancer, and the small molecule EGFR inhibitor erlotinib has been approved for pancreatic cancer therapy by the food and drug administration. Nevertheless, erlotinib alone is ineffective and should be combined with other drugs to improve therapeutic outcomes. We previously showed that certain receptor tyrosine kinase inhibitors can increase mitochondrial membrane potential (Δψm), facilitate tumor cell uptake of Δψm-sensitive agents, disrupt mitochondrial homeostasis, and subsequently trigger tumor cell death. Erlotinib has not been tested for this effect.

AIM

To determine whether erlotinib can elevate Δψm and increase tumor cell uptake of Δψm-sensitive agents, subsequently triggering tumor cell death.

METHODS

Δψm-sensitive fluorescent dye was used to determine how erlotinib affects Δψm in pancreatic adenocarcinoma (PDAC) cell lines. The viability of conventional and patient-derived primary PDAC cell lines in 2D- and 3D cultures was measured after treating cells sequentially with erlotinib and mitochondria-targeted ubiquinone (MitoQ), a Δψm-sensitive MitoQ. The synergy between erlotinib and MitoQ was then analyzed using SynergyFinder 2.0. The preclinical efficacy of the two-drug combination was determined using immune-compromised nude mice bearing PDAC cell line xenografts.

RESULTS

Erlotinib elevated Δψm in PDAC cells, facilitating tumor cell uptake and mitochondrial enrichment of Δψm-sensitive agents. MitoQ triggered caspase-dependent apoptosis in PDAC cells in culture if used at high doses, while erlotinib pretreatment potentiated low doses of MitoQ. SynergyFinder suggested that these drugs synergistically induced tumor cell lethality. Consistent with *in vitro* data, erlotinib and MitoQ combination suppressed human PDAC cell line xenografts in mice more effectively than single treatments of each agent.

CONCLUSION

Our findings suggest that a combination of erlotinib and MitoQ has the potential to suppress pancreatic tumor cell viability effectively.

**Key Words:** Pancreatic cancer; Erlotinib; Mitochondria-targeted ubiquinone; Mitochondria; Combination therapy

Leung PY, Chen W, Sari AN, Sitaram P, Wu PK, Tsai S, Park JI. Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival. *World J Gastroenterol* 2024; In press

**Core Tip:** In this study, we demonstrated that epidermal growth factor receptor inhibitor erlotinib increases mitochondrial membrane potential in pancreatic cancer cells, priming the tumor cells to mitochondria-targeted ubiquinone (MitoQ) sensitivity. Our data show that the combination of erlotinib and MitoQ can effectively and synergistically suppress pancreatic cancer cells *in vitro* and *in vivo*.

**INTRODUCTION**

Pancreatic cancer is a highly aggressive and poorly prognostic disease with an overall five-year survival rate of 12.5%[1,2]. Many molecular alternations have been identified and evaluated for their potential as a therapeutic target in pancreatic cancer[3]. Nevertheless, there is still an urgent need to develop an effective treatment for pancreatic cancer.

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) abnormally activated in many epithelial tumors, including non-small cell lung cancer (NSCLC)[4], glioblastoma[5], colon cancer[6], breast cancer[7], and pancreatic cancer[8]. Aberrantly activated EGFR promotes tumor cell proliferation and survival by activating critical signaling pathways such as the Ras/extracellular signal-regulated kinase, phosphatidylinositol-3 kinase/protein kinase B, and mammalian target of rapamycin pathways[9]. EGFR overexpression is a critical process for facilitating pancreatic tumorigenesis[10]. As such, the EGFR inhibitor erlotinib (Tarceva®) has been approved for treating pancreatic cancer. However, unlike its successful use for NSCLC as monotherapy[11], erlotinib is not as effective as monotherapy but is combined with gemcitabine to treat advanced pancreatic cancers[12-14]. Clinical trials have shown that erlotinib, in combination with capecitabine and chemoradiation, can also improve the survival of patients with resected pancreatic cancer[15,16]. Therefore, it is important to identify a combination therapy strategy to use erlotinib for effective pancreatic cancer therapy.

Certain RTK inhibitors (TKIs) affect mitochondrial activity, and this characteristic can be exploited to design a novel therapeutic strategy. For example, we previously showed that vandetanib and cabozantinib increase mitochondrial membrane potential (Δψm) in the RTK REarrangement during Transfection-mutated thyroid tumor cells and subsequently facilitate tumor cell uptake and retention of Δψm-sensitive mitochondria-targeted agents, including triphenyl-phosphonium (TPP)-mitochondria-targeted carboxy-proxyl (MitoCP) and mitochondria-targeted ubiquinone (MitoQ)[17]. This resulted in the accumulation of MitoCP and MitoQ in the tumor cell mitochondria, disrupting mitochondrial homeostasis and ultimately causing tumor cell death[17,18]. Of note, MitoQ is currently used as a dietary supplement due to its beneficial effects on mitochondrial bioenergetics[19,20] and vascular function[21-23], although this compound has been found to suppress tumor cells derived from the thyroid[17], skin[24], breast[25-27], and pancreas[28]. Therefore, selectively facilitating tumor cell enrichment of MitoQ using a TKI could be an effective strategy for tumor suppression. This strategy has not been tested for erlotinib.

Erlotinib is a TKI that targets multiple RTKs, including EGFR[29]. In this study, we tested a hypothesis that erlotinib increases Δψm in pancreatic tumor cells, hence priming the tumor cells to MitoQ sensitivity. Our data show that the combination of erlotinib and MitoQ can effectively and synergistically suppress pancreatic cancer cells *in vitro* and *in vivo*.

**MATERIALS AND METHODS**

***Cell culture and reagents***

The human pancreatic cancer cell line MiaPaCa-2 (ATCC) and pancreatic cancer cells-1 (PANC-1, ATCC) were maintained in Dulbecco’s minimal essential medium (DMEM, Gibco, Thermo Fisher Scientific,No. 11965) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, No. 16000-044) and 100 U/mL of penicillin-streptomycin (Gibco, Thermo Fisher Scientific, No. 15140) per mL. Patient-derived pancreatic cell lines MCW462 and MCW670 were previously described[30,31]. They were maintained in DMEM (Invitrogen, Thermo Fisher Scientific, No. 11330032) supplemented with 6% FBS, 100 U of penicillin-streptomycin, 50 µL of 100 μg/mL of epidermal growth factor (Thermo Fisher Scientific, No. PHG0311), 2 mL of bovine pituitary extract (Gibco, No. 13028014), 2 µg/mL of hydrocortisone (MilliporeSigma, St. Louis, MO, No. H0888) and 70 µL of insulin (Gibco, No. 12585014). For organoid culture, 10,000 cells were plated onto 24 well plates precoated with 200 µL Matrigel (Corning, Tewksbury, MA, No. 356231) and maintained with the DMEM medium mixed with Matrigel at 10% of final volume (0.8-1.1 mg/mL), as instructed by the manufacturer. Hypoxic cell culture was carried out in a humidified incubator with 1% O2, 5% CO2 and 94% N2. All experiments were performed using cells within ten passages from the acquisition point. Erlotinib was purchased from LC Laboratories (Woburn, MA, No. E-4997). Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone (ZVAD) and gemcitabine were purchased from Selleckchem (Houston, TX, No. S7023 and No. S1714). MitoCP was obtained from Dr. Balaraman Kalyanaraman (Biophysics, Medical College of Wisconsin). MitoQ [(10-(4,5-dimethoxy-2-methyl-3,6-dioxo-1,4-cyclohexadien-1-yl) decyl) triphenyl phosphonium]was obtained from MitoQ Ltd. (Auckland, New Zealand). Tetramethyl-rhodamine methyl ester (TMRM) was purchased from Invitrogen (No. T668). 4%-20% Mini-PROTEAN® TGX Stain-Free™ Protein Gels, 10 well, 30 µL were purchased from Bio-Rad (Hercules, CA, No. 4568093).

***Cell viability and cell cycle analyses***

The half maximal inhibitory concentration (IC50) values and the combination drug effects were determined by crystal violet staining (Fisher Chemical, Thermo Fisher Scientific, No. C58125). Briefly, cells in 96 well-plates were fixed in formaldehyde (Fisher Chemical, No. BP531), stained with 0.05% crystal violet for 30 min, washed with water three times, air-dried, and incubated in 200 µL methanol (VWR Chemicals BDH®, Radnor, PA, No. BDH1135) for 10 min at room temperature before measuring absorbance at 540 nm. The IC50 values in organoid cultures were determined using SYTOX™ Green (Invitrogen, No. S7020) following the manufacturer’s instruction. To determine apoptosis, cells were co-stained with annexin V (Invitrogen, No. A35122) and propidium iodide (Invitrogen, No. P1304MP) according to the manufacturer’s instruction. Flow cytometry was performed using BD® LSR II Flow Cytometer (Franklin Lakes, NJ). FCS data were analyzed by FCS EXPRESS software (De Novo Software, Los Angeles, California).

***Detection of mitochondrial membrane potential using TMRM***

Cells were incubated with culture medium with 2 nM TMRM (Invitrogen, No. T668) in 24-well plates for 30 min in a humidified incubator at 37 °C, collected by trypsinization, resuspended in phosphate-buffered saline containing 0.5% bovine serum albumin, and analyzed using Guava EasyCyte flow cytometry system. Data were analyzed by FCS EXPRESS software as described previously[27].

***Immunoblotting***

Mitochondrial fractions were extracted using the Mitochondria Isolation Kit for Cultured Cells (Thermo Fisher Scientific, No. 89874). Total cell lysates were prepared by harvesting cells in a lysis buffer containing 62.5 mmol/L Tris-HCl (pH 6.8), 2% sodium dodecyl sulfate (SDS), and the protease and phosphatase inhibitor cocktails 2 and 3 (MilliporeSigma, No. P8340, P5726, and P0044, respectively). Protein concentration was determined using the Pierce™ BCA Protein Assay Kit (Pierce, Thermo Fisher Scientific, No. 23227). Protein samples were resolved on the SDS-polyacrylamide gel electrophoresis and transferred to the polyvinylidene difluoride membrane filter (Bio-Rad, No. 1620177). After transfer, membranes were blocked in a buffer containing 0.1 M Tris (pH 7.4), 0.9% NaCl, 0.1% Tween 20, and 5% nonfat dry milk for 1 h at 25 °C. Membranes were then incubated with an appropriate antibody overnight at 4 °C with agitation at the following dilutions: Poly (ADP-ribose) polymerase (PARP) (cell signaling, No. 9542) 1: 2000; cleaved lamin A (cell signaling, No. 2035) 1: 1000; Caspase 9 (cell signaling, No. 9502T) 1: 2000; Caspase 3 (cell signaling, No. 14220); E2F1 (Thermo Fisher Scientific, No. MS-879) 1: 2000; pRb (cell signaling, No. 9307); cytochrome c oxidase subunit IV (COX IV, cell signaling, No. 4850) 1: 2000; p21CIP1 (Santa Cruz Biotechnology, No. sc-56335) 1:1000, p27KIP1 (Santa Cruz Biotechnology, No. sc-1641) 1:1000; hypoxia-inducible factor 1 subunit alpha (HIF1α, Cell Signaling, No. 14179) 1:1000 and β-actin (MilliporeSigma, No. A2228) 1:5000. Chemiluminescence signals of immunoblots were visualized by SuperSignal West Pico (No. 34079) and Femto (No. 23227) chemiluminescence kits (Pierce), captured by ChemiDoc XRS+ (Bio-Rad), and analyzed by Image Lab software (Bio-Rad) for densitometry.

***Tumor xenografts***

A total of 5 × 106 PANC-1 cells suspended in 100 µL of Hank’s balanced salt solution (Gibco, No. 14025) mixed with Extracellular Matrix Gel (MilliporeSigma, No. E6909) at 1:1 ratio was inoculated subcutaneously into the rear flanks of 6-week-old female athymic nude (*nu*/*nu*) mice (The Jackson Laboratory, Bar Harbour, ME, No. 007850). Once palpable, tumors were measured using Vernier calipers twice a week. Tumor volumes were calculated using the formula: Length × width × height × 0.5236. When tumor volumes reached 50 mm3, mice were sorted into 4 groups of 7 animals to achieve equal tumor size distribution in all treatment groups. Mice were treated with vehicle, MitoQ, erlotinib, and the combination of two compounds (combo), respectively. Drugs dissolved in 100 μL vehicle (1:12 mixture of Dimethyl sulfoxide /15% β-cyclodextrin) were orally administered by gavage daily for 4 d, followed by one day break. Four cycles of this treatment were conducted. The control group received only the vehicle, the MitoQ group received 20 mg drug/kg body weight/dose, the erlotinib group received 25 mg drug/kg body weight/dose, and the combination group received two doses of erlotinib followed by two doses of MitoQ in a cycle. Ethical endpoints were when tumor size reached 2000 mm3. At the end of the experiments, animals were euthanized by CO2 asphyxiation, and tumor tissues were harvested. All animal studies were performed according to protocols approved by the Institutional Animal Care and Use Committee at the Medical College of Wisconsin, No. AUA00001327.

***Statistical analysis***

Unless otherwise specified, all graphs represent the mean ± the standard error of mean from biological replicates (*N* ≥ 3). Statistical significance was determined by one-way or two-way analysis of variance with Bonferroni post-tests and two-tailed unpaired Student’s *t*-test using PRISM (Graph-Pad Software, La Jolla, CA). IC50 was determined by PRISM. *P* values of < 0.05 were considered statistically significant.

**RESULTS**

***MitoQ can suppress the viability of pancreatic ductal adenocarcinoma cells***

We determined how MitoQ affects pancreatic adenocarcinoma (PDAC) cell viability in a cell line panel that included the conventional PDAC cell lines PANC-1 and MiaPaCa-2 and the patient-derived PDAC cell lines MCW462 and MCW670. As determined by the crystal violet viability assay, 48 h MitoQ treatment significantly decreased cell viability in the two-dimensional cell culture with the IC50 values determined below 1 µM in all cell lines (Figure 1A and B). In contrast, the functional moiety of MitoQ CoQ10 (ubiquinone) did not suppress cell viability, while the vehicle moiety TPP decreased cell viability mildly only at higher doses (Figure1A). The organoid culture model is more physiologically relevant[32], and we also examined MitoQ responsiveness of MCW462 cells in organoid cultures. As determined by Sytox Green viability assay, MitoQ, but not CoQ10 and TPP, consistently decreased the viability of MCW462 cells in the organoid culture (Figure1C). However, the IC50 value was higher in the three-dimensional culture. These data demonstrate that MitoQ can suppress PDAC cell viability, for which the mitochondrial targeting of its functional moiety might be critical.

***MitoQ can induce caspase-dependent apoptosis in* *pancreatic ductal adenocarcinoma cells***

To determine the molecular mechanism by which MitoQ suppresses PDAC cell viability, we performed the annexin V/propidium Iodide co-staining assay. We found that, if used at a high dose, MitoQ increased annexin V positive population in MiaPaCa-2 and MCW670 cultures (Figure 2A). However, the control CoQ10 and TPP did not show similar effects. This effect of MitoQ was significantly blocked by the pan-caspase inhibitor ZVAD (Figure 2A). Moreover, Western blot analysis of total lysates of these cells revealed that MitoQ, but not TPP or CoQ10, notably increased the cleavages of PARP and lamin A in a dose-dependent manner (Figure 2B). The cleavage of these proteins is a bonafide marker of caspase-dependent apoptosis[33]. Indeed, 5 µM MitoQ increased the cleavage of caspases 9 and 3 in MiaPaCa-2 cells while depleting these enzymes in MCW670 cells (Figure 2B). We also found that MitoQ decreased E2F1, the S-phase transcription factor[34], and the phosphorylation of its regulator Rb while increasing the cyclin-dependent kinase inhibitor p27KIP1 without notably affecting p21CIP1 levels in these cells (Figure 2B). These data suggest that MitoQ can suppress PDAC cell viability by inducing caspase-dependent apoptosis and partly by suppressing a few critical regulators for cell cycle progression.

***Erlotinib can increase mitochondrial membrane potential and facilitate mitochondrial enrichment of mitochondrial membrane potential-sensitive agents in pancreatic ductal adenocarcinoma cells***

We determined whether erlotinib can increase Δψm in PDAC cells. In the cultures of multiple PDAC cell lines, erlotinib treatment significantly increased cells stained with TMRM, a Δψm-sensitive fluorescent dye, in a dose-dependent manner within 48 h (Figure 3A and B). Given this data, we determined whether erlotinib can increase the mitochondrial enrichment of a Δψm-sensitive agent using the TPP-conjugated superoxide dismutase mimetic MitoCP as a tool compound. The CP moiety of MitoCP is a 5-membered nitroxide free radical that can form a covalent conjugate with thiol proteins, which can be detected by a TPP-specific antibody[17,35]. When the mitochondrial extracts from MitoCP-treated PANC-1 and MCW462 cells were analyzed for the effects of 24 h erlotinib pretreatment, western blotting revealed much higher levels of TPP-protein adducts in erlotinib-pretreated cells (Figure 3C). These data suggest that erlotinib can increase Δψm and, subsequently, mitochondrial enrichment of a Δψm-sensitive agent in PDAC cells.

***Erlotinib and MitoQ can synergistically suppress the viability of pancreatic ductal adenocarcinoma cells in culture***

Given the data above, we asked whether erlotinib can synergize with MitoQ to suppress PDAC cell viability. As determined in PANC-1, MCW462, and MCW670 cells, a robust viability loss was induced when these cells were sequentially treated with erlotinib for the first 24 h and MitoQ for the subsequent 48 h (Figure 4A). Of note, our analysis using SynergyFinder 2.0[36] suggested that these two agents synergistically induced the viability loss (Figure 4B). Importantly, tumor cells in a physiological microenvironment are generally under a hypoxic condition[37]. We, therefore, determined whether the erlotinib-MitoQ combination can produce a similar synergistic effect under a hypoxic culture condition. To this end, we used PANC-1 cells maintained in the human plasma-like medium with 1% O2, under which condition HIF1α expression substantially increased (Figure 4C). Under this hypoxic culture condition, the combination of erlotinib and MitoQ consistently suppressed the viability of PANC-1 cells (Figure 4D), through a synergistic effect as suggested by SynergyFinder 2.0 (Figure 4E). These data strongly suggest that erlotinib can synergize with MitoQ to suppress PDAC cells.

***A combination of erlotinib and MitoQ effectively suppresses the growth of pancreatic cancer cells xenografts in mice***

PANC-1 cells express relatively higher EGFR[38]. Given this information and the relatively high synergy score in this cell line (Figure 4), we used immune-compromised nude mice bearing PANC-1 xenografts to determine the preclinical efficacy of the erlotinib and MitoQ combination. These mice were subjected to 4 cycles of treatments in which erlotinib and MitoQ were orally administered singly or in combination (depicted in Figure 5A). For the drug combination, a cycle consisted of 2 d erlotinib treatment followed by 2 d MitoQ treatment and one drug holiday (Figure 5A), which is similar as the schedule that we previously used for preclinical evaluation of the vandetanib and MitoCP combination for thyroid cancer[17]. To compare mono- and combination therapies, we used erlotinib at 25 mg/kg/dose, a lower dose than the highly potent doses (50 mg/kg once daily) in the other preclinical models[39,40]. Likewise, we used MitoQ at 20 mg/kg/dose, which did not significantly suppress tumor growth in a preclinical breast cancer model, albeit decreasing tumor metastasis[26]. Consistent with the *in vitro* data above, the sequential administration of erlotinib and MitoQ suppressed the growth of PANC-1 xenografts more effectively than the monotherapy using each agent, as determined by monitoring tumor volume changes (Figure 5B) and by measuring the sizes and weight of tumors harvested at the end of the treatment (Figure 5C and D). In contrast, these treatments did not cause a significant difference in animal body weights (Figure 5E). These data suggest that erlotinib can synergize with MitoQ *in vivo* to suppress the growth of PDAC cells.

**DISCUSSION**

Our data show that MitoQ can suppress PDAC cell survival if used at an effective dose. Similarly, tumor cells derived from thyroid, skin, and breast cancers have shown sensitivity to MitoQ[24,25,27]. Many tumor cells exhibit elevated steady-state Δψm, which is required for adaptation to hypoxia, escape from anoikis, and enhanced invasiveness[41,42]. For this reason, MitoQ would accumulate higher in the mitochondria of tumor cells than those of most normal cell types[23], which might increase the chance for MitoQ to exert any adverse effect on tumor cells. Our data suggest that the property of erlotinib to increase Δψm in PDAC cells can be exploited to drive the mitochondrial enrichment of MitoQ in PDAC cells.

How does MitoQ kill tumor cells? Reactive oxygen species (ROS) produced in tumor cells are supposed to promote tumorigenesis, angiogenesis, metastasis, and chemoresistance[43,44]. Given this, tumor cells may be more susceptible to ROS scavenging. Indeed, an oxidized form of ubiquinone (BPM31510) is currently in clinical trial to treat solid tumors with a high ROS burden[45], and MitoQ may act in a similar fashion. In support of this notion, MitoQ can decrease ROS generation through the NRF 2/NAD(P)H quinone oxidoreductase 1 pathway, a key endogenous antioxidant defense mechanism[27,46,47]. Moreover, MitoQ was shown to inhibit redox signaling to prevent PDAC metastasis in mice[28]. However, in contrast, studies using bovine aortic endothelial cells demonstrated that MitoQ can also increase ROS generation in mitochondria[48,49]. Mechanistically, MitoQ can be reduced by complex II, but not by complexes I and III due to the bulkiness and positive charge of its TPP moiety that sterically hindered access to the proteins[50,51]. Therefore, MitoQ is anti- as well as pro-oxidant, depending on cell types. In either scenario, MitoQ over-enrichment would harm cells.

How does erlotinib increase ΔΨm? Although not widely known, EGFR can translocate to mitochondria and regulate different mitochondria processes[52-55]. For example, EGFR translocation to the outer membrane of mitochondria promotes mitochondrial fission by disturbing the polymerization of the mitochondria fusion protein mitofusin 1 through direct interaction, which promotes the metastatic potential of NSCLC cells[55]. EGFR can directly bind to cytochrome c oxidase subunit II (COXII) in mitochondria[54], which leads to COXII phosphorylation and activity loss[56,57]. Increased COXII activity is implicated in hyperpolarization of mitochondria under conditions such as ischemia-reperfusion[58]. Because erlotinib abolished COXII inhibition by EGFR[59], a COXII regulation may underlie erlotinib-induced elevation of ΔΨm in PDAC cells. Alternatively, EGFR may use a signaling pathway to regulate ΔΨm. For example, a deficiency of mechanistic target of rapamycin (mTOR) complex 2 and mTOR inhibition can cause ΔΨm elevation in different cell types, including lung and breast tumor cells[60-62]. Because EGFR regulates mTOR[63,64], it may be possible that erlotinib affects ΔΨm *via* the mTOR pathway. Although we hypothesize that ΔΨm-dependent mitochondrial over-enrichment of MitoQ is the primary mechanism underlying the synergy between MitoQ and erlotinib, we also appreciate additional possibilities. For example, MitoQ can induce mitophagy *via* the PTEN-induced kinase 1/Parkin RBR E3 ubiquitin-protein ligase pathway[65,66], and erlotinib can induce autophagy through p53 nuclear translocation, AMP-activated protein kinase activation, and mTOR suppression[67,68]. Therefore, it is also possible that MitoQ and erlotinib synergize in the context of autophagic cell death. Interrogation of these mechanisms remains as future studies.

**CONCLUSION**

Although MitoQ has been tested for its clinical potential for different diseases[21-23], it has not been tested for cancer therapy in a clinical trial setting. Based on the data in this study, we suggest that MitoQ can potentially suppress PDAC cell survival and that its combination with erlotinib is a candidate strategy to target PDAC cells selectively. MitoQ has additional potential benefits because antioxidants can support the physical fitness of patients undergoing chemotherapy[69,70]. In support of this notion, MitoQ improved muscle atrophy and weakness in colon cancer cell line tumor-bearing mice[70]. Studies have shown that TKIs, including ponatinib, regorafenib, sunitinib, imatinib, and sorafenib, can also affect ΔΨm, although their effects vary depending upon cell types[61,71-73]. Our findings lay a foundation to evaluate these TKIs in a similar context for the combination therapy concept.

**ARTICLE HIGHLIGHTS**

***Research background***

We previously showed that receptor tyrosine kinase inhibitors such as cabozantinib and vandetanib can increase mitochondrial membrane potential (Δψm) in tumor cells and, thus, facilitate mitochondrial enrichment of Δψm-sensitive agents in tumor cells. This effect can disrupt mitochondrial homeostasis and trigger tumor cell death.

***Research motivation***

Pancreatic cancer is one of the most lethal tumors, demanding highly effective molecular therapies. Although the epidermal growth factor receptor inhibitor erlotinib has been approved for pancreatic adenocarcinoma (PDAC), its efficacy is limited as monotherapy, and it is often used in combination with other drugs. We sought to determine whether erlotinib can be combined with a mitochondria-targeted agent for PDAC suppression.

***Research methods***

We measured cell viability by performing cell death assays in 2D and 3D cultures of conventional and patient-derived primary PDAC cell lines. We determined how erlotinib affects Δψm in PDAC cells using Δψm-sensitive fluorescent dyes and by measuring protein adduct formation with mitochondria-targeted carboxy-proxyl (MitoCP) in mitochondria. We examined the effect of erlotinib and mitochondria-targeted ubiquinone (MitoQ) combination by measuring cell viability and analyzing synergy. We determined the preclinical efficacy and physiological relevance of the drug combination using immune-compromised nude mice bearing PDAC cell line xenografts.

***Research results***

Erlotinib elevated Δψm in PDAC cells and facilitated mitochondrial enrichment of the triphenyl-phosphonium (TPP)-conjugated agents. While MitoQ single treatment triggered caspase-dependent apoptosis in PDAC cells, its combination with erlotinib synergistically induced PDAC cell death. Consistent with these data, the drug combination suppressed human PDAC cell line xenografts in mice more effectively than a single treatment of each agent.

***Research conclusions***

These data suggest that erlotinib elevated Δψm in PDAC cells and facilitated mitochondrial enrichment of the TPP-conjugated agents. The drug combination synergistically suppressed PDAC cells.

***Research objectives***

We aimed to determine whether erlotinib elevates Δψm in PDAC cells, increases tumor cell uptake of the TPP cation-conjugated ubiquinone MitoQ, and subsequently causes tumor cell death.

***Research perspectives***

These data suggest that the erlotinib and MitoQ combination may have therapeutic potential for pancreatic cancer.

**ACKNOWLEDGEMENTS**

We thank MitoQ Ltd. (Auckland, New Zealand) for MitoQ, Dr. Michael Murphy (Medical Research Council Dunn Human Nutrition Unit) for the TPP antibody, Drs. Balaraman Kalyanaraman and Gang Cheng (Medical College of Wisconsin) for MitoCP.

**REFERENCES**

1 **Oliveira-Cunha M**, Newman WG, Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. *Cancers (Basel)* 2011; **3**: 1513-1526 [PMID: 24212772 DOI: 10.3390/cancers3021513]

2 **National Cancer Institute: Surveillance E, and End Results Program**. ICD-O-3/WHO 2008. [cited January 20, 2023]. Available from: https://seer.cancer.gov/statfacts/html/thyro.html

3 **Rodríguez Gil Y**, Jiménez Sánchez P, Muñoz Velasco R, García García A, Sánchez-Arévalo Lobo VJ. Molecular Alterations in Pancreatic Cancer: Transfer to the Clinic. *Int J Mol Sci* 2021; **22** [PMID: 33669845 DOI: 10.3390/ijms22042077]

4 **Lynch TJ**, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004; **350**: 2129-2139 [PMID: 15118073 DOI: 10.1056/NEJMoa040938]

5 **Brennan CW**, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L; TCGA Research Network. The somatic genomic landscape of glioblastoma. *Cell* 2013; **155**: 462-477 [PMID: 24120142 DOI: 10.1016/j.cell.2013.09.034]

6 **Ooi A**, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, Fujii H, Takeda Y, Dobashi Y. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. *Mod Pathol* 2004; **17**: 895-904 [PMID: 15143334 DOI: 10.1038/modpathol.3800137]

7 **Bhargava R**, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. *Mod Pathol* 2005; **18**: 1027-1033 [PMID: 15920544 DOI: 10.1038/modpathol.3800438]

8 **Eberl M**, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K, Schnidar H, Hache H, Bauer HC, Solca F, Hauser-Kronberger C, Ermilov AN, Verhaegen ME, Bichakjian CK, Dlugosz AA, Nietfeld W, Sibilia M, Lehrach H, Wierling C, Aberger F. Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells. *EMBO Mol Med* 2012; **4**: 218-233 [PMID: 22294553 DOI: 10.1002/emmm.201100201]

9 **Wee P**, Wang Z. Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. *Cancers (Basel)* 2017; **9** [PMID: 28513565 DOI: 10.3390/cancers9050052]

10 **Friess H**, Kleeff J, Korc M, Büchler MW. Molecular aspects of pancreatic cancer and future perspectives. *Dig Surg* 1999; **16**: 281-290 [PMID: 10449972 DOI: 10.1159/000018737]

11 **Cohen MH**, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: erlotinib (Tarceva) tablets. *Oncologist* 2005; **10**: 461-466 [PMID: 16079312 DOI: 10.1634/theoncologist.10-7-461]

12 **Abdelgalil AA**, Al-Kahtani HM, Al-Jenoobi FI. Erlotinib. *Profiles Drug Subst Excip Relat Methodol* 2020; **45**: 93-117 [PMID: 32164971 DOI: 10.1016/bs.podrm.2019.10.004]

13 **Fountzilas C**, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. *Cancer Chemother Pharmacol* 2017; **80**: 497-505 [PMID: 28702772 DOI: 10.1007/s00280-017-3375-9]

14 **Moore MJ**, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; **25**: 1960-1966 [PMID: 17452677 DOI: 10.1200/JCO.2006.07.9525]

15 **Ma WW**, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M. A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer. *Transl Oncol* 2010; **3**: 373-379 [PMID: 21151476 DOI: 10.1593/tlo.10196]

16 **Herman JM**, Fan KY, Wild AT, Hacker-Prietz A, Wood LD, Blackford AL, Ellsworth S, Zheng L, Le DT, De Jesus-Acosta A, Hidalgo M, Donehower RC, Schulick RD, Edil BH, Choti MA, Hruban RH, Pawlik TM, Cameron JL, Laheru DA, Wolfgang CL. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 2013; **86**: 678-685 [PMID: 23773391 DOI: 10.1016/j.ijrobp.2013.03.032]

17 **Starenki D**, Hong SK, Wu PK, Park JI. Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells. *Cancer Biol Ther* 2017; **18**: 473-483 [PMID: 28475408 DOI: 10.1080/15384047.2017.1323594]

18 **Starenki D**, Park JI. Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo. *J Clin Endocrinol Metab* 2013; **98**: 1529-1540 [PMID: 23509102 DOI: 10.1210/jc.2012-3671]

19 **Kelso GF**, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, Smith RA, Murphy MP. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. *J Biol Chem* 2001; **276**: 4588-4596 [PMID: 11092892 DOI: 10.1074/jbc.M009093200]

20 **Murphy MP**, Smith RA. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. *Annu Rev Pharmacol Toxicol* 2007; **47**: 629-656 [PMID: 17014364 DOI: 10.1146/annurev.pharmtox.47.120505.105110]

21 **Hager WD**, Wiesner PJ. Selected epidemiologic aspects of acute salpingitis: a review. *J Reprod Med* 1977; **19**: 47-50 [PMID: 327062 DOI: 10.1152/ajpheart.00235.2020]

22 **Rossman MJ**, Santos-Parker JR, Steward CAC, Bispham NZ, Cuevas LM, Rosenberg HL, Woodward KA, Chonchol M, Gioscia-Ryan RA, Murphy MP, Seals DR. Chronic Supplementation With a Mitochondrial Antioxidant (MitoQ) Improves Vascular Function in Healthy Older Adults. *Hypertension* 2018; **71**: 1056-1063 [PMID: 29661838 DOI: 10.1161/HYPERTENSIONAHA.117.10787]

23 **Smith RA**, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. *Ann N Y Acad Sci* 2010; **1201**: 96-103 [PMID: 20649545 DOI: 10.1111/j.1749-6632.2010.05627.x]

24 **Hong SK**, Starenki D, Wu PK, Park JI. Suppression of B-Raf(V600E) melanoma cell survival by targeting mitochondria using triphenyl-phosphonium-conjugated nitroxide or ubiquinone. *Cancer Biol Ther* 2017; **18**: 106-114 [PMID: 27786591 DOI: 10.1080/15384047.2016.1250987]

25 **Capeloa T**, Krzystyniak J, d'Hose D, Canas Rodriguez A, Payen VL, Zampieri LX, Van de Velde JA, Benyahia Z, Pranzini E, Vazeille T, Fransolet M, Bouzin C, Brusa D, Michiels C, Gallez B, Murphy MP, Porporato PE, Sonveaux P. MitoQ Inhibits Human Breast Cancer Cell Migration, Invasion and Clonogenicity. *Cancers (Basel)* 2022; **14** [PMID: 35326667 DOI: 10.3390/cancers14061516]

26 **Capeloa T**, Krzystyniak J, Rodriguez AC, Payen VL, Zampieri LX, Pranzini E, Derouane F, Vazeille T, Bouzin C, Duhoux FP, Murphy MP, Porporato PE, Sonveaux P. MitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice. *Cancers (Basel)* 2022; **14** [PMID: 35326639 DOI: 10.3390/cancers14061488]

27 **Rao VA**, Klein SR, Bonar SJ, Zielonka J, Mizuno N, Dickey JS, Keller PW, Joseph J, Kalyanaraman B, Shacter E. The antioxidant transcription factor Nrf2 negatively regulates autophagy and growth arrest induced by the anticancer redox agent mitoquinone. *J Biol Chem* 2010; **285**: 34447-34459 [PMID: 20805228 DOI: 10.1074/jbc.M110.133579]

28 **Capeloa T**, Van de Velde JA, d'Hose D, Lipari SG, Derouane F, Hamelin L, Bedin M, Vazeille T, Duhoux FP, Murphy MP, Porporato PE, Gallez B, Sonveaux P. Inhibition of Mitochondrial Redox Signaling with MitoQ Prevents Metastasis of Human Pancreatic Cancer in Mice. *Cancers (Basel)* 2022; **14** [PMID: 36230841 DOI: 10.3390/cancers14194918]

29 **Zhou Y**, Zhang Y, Zou H, Cai N, Chen X, Xu L, Kong X, Liu P. The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells. *Sci Rep* 2015; **5**: 8629 [PMID: 25720956 DOI: 10.1038/srep08629]

30 **Tsai S**, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. *BMC Cancer* 2018; **18**: 335 [PMID: 29587663 DOI: 10.1186/s12885-018-4238-4]

31 **Clarke WR**, Amundadottir L, James MA. CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells. *Int J Cancer* 2019; **144**: 1367-1378 [PMID: 30468251 DOI: 10.1002/ijc.32012]

32 **Kim J**, Koo BK, Knoblich JA. Human organoids: model systems for human biology and medicine. *Nat Rev Mol Cell Biol* 2020; **21**: 571-584 [PMID: 32636524 DOI: 10.1038/s41580-020-0259-3]

33 **Rosen A**, Casciola-Rosen L. Macromolecular substrates for the ICE-like proteases during apoptosis. *J Cell Biochem* 1997; **64**: 50-54 [PMID: 9015754 DOI: 10.1002/(sici)1097-4644(199701)64:1<50::aid-jcb8>3.0.co;2-z]

34 **He S**, Cook BL, Deverman BE, Weihe U, Zhang F, Prachand V, Zheng J, Weintraub SJ. E2F is required to prevent inappropriate S-phase entry of mammalian cells. *Mol Cell Biol* 2000; **20**: 363-371 [PMID: 10594038 DOI: 10.1128/MCB.20.1.363-371.2000]

35 **Lin TK**, Hughes G, Muratovska A, Blaikie FH, Brookes PS, Darley-Usmar V, Smith RA, Murphy MP. Specific modification of mitochondrial protein thiols in response to oxidative stress: a proteomics approach. *J Biol Chem* 2002; **277**: 17048-17056 [PMID: 11861642 DOI: 10.1074/jbc.M110797200]

36 **Ianevski A**, Giri AK, Aittokallio T. SynergyFinder 2.0: visual analytics of multi-drug combination synergies. *Nucleic Acids Res* 2020; **48**: W488-W493 [PMID: 32246720 DOI: 10.1093/nar/gkaa216]

37 **Hompland T**, Fjeldbo CS, Lyng H. Tumor Hypoxia as a Barrier in Cancer Therapy: Why Levels Matter. *Cancers (Basel)* 2021; **13** [PMID: 33525508 DOI: 10.3390/cancers13030499]

38 **Ali S**, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. *Mol Cancer Ther* 2005; **4**: 1943-1951 [PMID: 16373709 DOI: 10.1158/1535-7163.MCT-05-0065]

39 **Lee KJ**, Wright G, Bryant H, Wiggins LA, Schuler M, Gassman NR. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer. *Cancer Drug Resist* 2020; **3**: 980-991 [PMID: 35582228 DOI: 10.20517/cdr.2020.73]

40 **Nagaraj NS**, Washington MK, Merchant NB. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. *Clin Cancer Res* 2011; **17**: 483-493 [PMID: 21266529 DOI: 10.1158/1078-0432.CCR-10-1670]

41 **Mani S**, Swargiary G, Singh KK. Natural Agents Targeting Mitochondria in Cancer. *Int J Mol Sci* 2020; **21** [PMID: 32977472 DOI: 10.3390/ijms21196992]

42 **Heerdt BG**, Houston MA, Augenlicht LH. Growth properties of colonic tumor cells are a function of the intrinsic mitochondrial membrane potential. *Cancer Res* 2006; **66**: 1591-1596 [PMID: 16452217 DOI: 10.1158/0008-5472.CAN-05-2717]

43 **Szatrowski TP**, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. *Cancer Res* 1991; **51**: 794-798 [PMID: 1846317]

44 **Galadari S**, Rahman A, Pallichankandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: To promote or to suppress? *Free Radic Biol Med* 2017; **104**: 144-164 [PMID: 28088622 DOI: 10.1016/j.freeradbiomed.2017.01.004]

45 **Dadali T**, Diers AR, Kazerounian S, Muthuswamy SK, Awate P, Ng R, Mogre S, Spencer C, Krumova K, Rockwell HE, McDaniel J, Chen EY, Gao F, Diedrich KT, Vemulapalli V, Rodrigues LO, Akmaev VR, Thapa K, Hidalgo M, Bose A, Vishnudas VK, Moser AJ, Granger E, Kiebish MA, Gesta S, Narain NR, Sarangarajan R. Elevated levels of mitochondrial CoQ(10) induce ROS-mediated apoptosis in pancreatic cancer. *Sci Rep* 2021; **11**: 5749 [PMID: 33707480 DOI: 10.1038/s41598-021-84852-z]

46 **Zhou J**, Wang H, Shen R, Fang J, Yang Y, Dai W, Zhu Y, Zhou M. Mitochondrial-targeted antioxidant MitoQ provides neuroprotection and reduces neuronal apoptosis in experimental traumatic brain injury possibly via the Nrf2-ARE pathway. *Am J Transl Res* 2018; **10**: 1887-1899 [PMID: 30018728]

47 **Xiao L**, Xu X, Zhang F, Wang M, Xu Y, Tang D, Wang J, Qin Y, Liu Y, Tang C, He L, Greka A, Zhou Z, Liu F, Dong Z, Sun L. The mitochondria-targeted antioxidant MitoQ ameliorated tubular injury mediated by mitophagy in diabetic kidney disease via Nrf2/PINK1. *Redox Biol* 2017; **11**: 297-311 [PMID: 28033563 DOI: 10.1016/j.redox.2016.12.022]

48 **Doughan AK**, Dikalov SI. Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis. *Antioxid Redox Signal* 2007; **9**: 1825-1836 [PMID: 17854275 DOI: 10.1089/ars.2007.1693]

49 **O'Malley Y**, Fink BD, Ross NC, Prisinzano TE, Sivitz WI. Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. *J Biol Chem* 2006; **281**: 39766-39775 [PMID: 17060316 DOI: 10.1074/jbc.M608268200]

50 **James AM**, Cochemé HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. *J Biol Chem* 2005; **280**: 21295-21312 [PMID: 15788391 DOI: 10.1074/jbc.M501527200]

51 **James AM**, Sharpley MS, Manas AR, Frerman FE, Hirst J, Smith RA, Murphy MP. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. *J Biol Chem* 2007; **282**: 14708-14718 [PMID: 17369262 DOI: 10.1074/jbc.M611463200]

52 **Yue X**, Song W, Zhang W, Chen L, Xi Z, Xin Z, Jiang X. Mitochondrially localized EGFR is subjected to autophagic regulation and implicated in cell survival. *Autophagy* 2008; **4**: 641-649 [PMID: 18398293 DOI: 10.4161/auto.5971]

53 **Zhang C**, Jin Y, Marchetti M, Lewis MR, Hammouda OT, Edgar BA. EGFR signaling activates intestinal stem cells by promoting mitochondrial biogenesis and β-oxidation. *Curr Biol* 2022; **32**: 3704-3719.e7 [PMID: 35896119 DOI: 10.1016/j.cub.2022.07.003]

54 **Boerner JL**, Demory ML, Silva C, Parsons SJ. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. *Mol Cell Biol* 2004; **24**: 7059-7071 [PMID: 15282306 DOI: 10.1128/MCB.24.16.7059-7071.2004]

55 **Che TF**, Lin CW, Wu YY, Chen YJ, Han CL, Chang YL, Wu CT, Hsiao TH, Hong TM, Yang PC. Mitochondrial translocation of EGFR regulates mitochondria dynamics and promotes metastasis in NSCLC. *Oncotarget* 2015; **6**: 37349-37366 [PMID: 26497368 DOI: 10.18632/oncotarget.5736]

56 **Demory ML**, Boerner JL, Davidson R, Faust W, Miyake T, Lee I, Hüttemann M, Douglas R, Haddad G, Parsons SJ. Epidermal growth factor receptor translocation to the mitochondria: regulation and effect. *J Biol Chem* 2009; **284**: 36592-36604 [PMID: 19840943 DOI: 10.1074/jbc.M109.000760]

57 **Lee I**, Salomon AR, Ficarro S, Mathes I, Lottspeich F, Grossman LI, Hüttemann M. cAMP-dependent tyrosine phosphorylation of subunit I inhibits cytochrome c oxidase activity. *J Biol Chem* 2005; **280**: 6094-6100 [PMID: 15557277 DOI: 10.1074/jbc.M411335200]

58 **Hüttemann M**, Helling S, Sanderson TH, Sinkler C, Samavati L, Mahapatra G, Varughese A, Lu G, Liu J, Ramzan R, Vogt S, Grossman LI, Doan JW, Marcus K, Lee I. Regulation of mitochondrial respiration and apoptosis through cell signaling: cytochrome c oxidase and cytochrome c in ischemia/reperfusion injury and inflammation. *Biochim Biophys Acta* 2012; **1817**: 598-609 [PMID: 21771582 DOI: 10.1016/j.bbabio.2011.07.001]

59 **Momcilovic M**, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. *Cell Rep* 2017; **18**: 601-610 [PMID: 28099841 DOI: 10.1016/j.celrep.2016.12.061]

60 **Betz C**, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N, Hall MN. Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. *Proc Natl Acad Sci U S A* 2013; **110**: 12526-12534 [PMID: 23852728 DOI: 10.1073/pnas.1302455110]

61 **Gorzalczany Y**, Gilad Y, Amihai D, Hammel I, Sagi-Eisenberg R, Merimsky O. Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer. *Cancer Lett* 2011; **310**: 207-215 [PMID: 21807458 DOI: 10.1016/j.canlet.2011.07.002]

62 **Paglin S**, Lee NY, Nakar C, Fitzgerald M, Plotkin J, Deuel B, Hackett N, McMahill M, Sphicas E, Lampen N, Yahalom J. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. *Cancer Res* 2005; **65**: 11061-11070 [PMID: 16322256 DOI: 10.1158/0008-5472.CAN-05-1083]

63 **Freudlsperger C**, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C. EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. *Expert Opin Ther Targets* 2011; **15**: 63-74 [PMID: 21110697 DOI: 10.1517/14728222.2011.541440]

64 **Fan QW**, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. EGFR signals to mTOR through PKC and independently of Akt in glioma. *Sci Signal* 2009; **2**: ra4 [PMID: 19176518 DOI: 10.1126/scisignal.2000014]

65 **Dou SD**, Zhang JN, Xie XL, Liu T, Hu JL, Jiang XY, Wang MM, Jiang HD. MitoQ inhibits hepatic stellate cell activation and liver fibrosis by enhancing PINK1/parkin-mediated mitophagy. *Open Med (Wars)* 2021; **16**: 1718-1727 [PMID: 34825063 DOI: 10.1515/med-2021-0394]

66 **Ji Y**, Leng Y, Lei S, Qiu Z, Ming H, Zhang Y, Zhang A, Wu Y, Xia Z. The mitochondria-targeted antioxidant MitoQ ameliorates myocardial ischemia-reperfusion injury by enhancing PINK1/Parkin-mediated mitophagy in type 2 diabetic rats. *Cell Stress Chaperones* 2022; **27**: 353-367 [PMID: 35426609 DOI: 10.1007/s12192-022-01273-1]

67 **Li YY**, Lam SK, Mak JC, Zheng CY, Ho JC. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer. *Lung Cancer* 2013; **81**: 354-361 [PMID: 23769318 DOI: 10.1016/j.lungcan.2013.05.012]

68 **Lypova N**, Dougherty SM, Lanceta L, Chesney J, Imbert-Fernandez Y. PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs. *Cells* 2021; **10** [PMID: 34359849 DOI: 10.3390/cells10071679]

69 **Drisko JA**, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. *J Am Coll Nutr* 2003; **22**: 118-123 [PMID: 12672707 DOI: 10.1080/07315724.2003.10719284]

70 **Pin F**, Huot JR, Bonetto A. The Mitochondria-Targeting Agent MitoQ Improves Muscle Atrophy, Weakness and Oxidative Metabolism in C26 Tumor-Bearing Mice. *Front Cell Dev Biol* 2022; **10**: 861622 [PMID: 35392166 DOI: 10.3389/fcell.2022.861622]

71 **Paech F**, Mingard C, Grünig D, Abegg VF, Bouitbir J, Krähenbühl S. Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells. *Toxicology* 2018; **395**: 34-44 [PMID: 29341879 DOI: 10.1016/j.tox.2018.01.005]

72 **French KJ**, Coatney RW, Renninger JP, Hu CX, Gales TL, Zhao S, Storck LM, Davis CB, McSurdy-Freed J, Chen E, Frazier KS. Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity. *Toxicol Pathol* 2010; **38**: 691-702 [PMID: 20616376 DOI: 10.1177/0192623310373775]

73 **Qian X**, Li J, Ding J, Wang Z, Zhang W, Hu G. Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549. *Clin Exp Pharmacol Physiol* 2009; **36**: 487-494 [PMID: 19673930 DOI: 10.1111/j.1440-1681.2008.05091.x]

**Footnotes**

**Institutional review board statement:** This letter is to confirm that this study doesn't involve any human subjects.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the Medical College of Wisconsin (AUA00001327).

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Data sharing statement:** All data needed to evaluate the conclusions in the paper are present in the paper. Any additional information required to reanalyze the data reported in this paper is available from the corresponding authors upon request. Reagents and materials produced in this study are available pending a completed Materials Transfer Agreement.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** September 26, 2023

**First decision:** October 9, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Gao W, China; Qi L, China **S-Editor:** Qu XL **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Mitochondria-targeted ubiquinone can suppress the viability of pancreatic adenocarcinoma cells.** A: pancreatic adenocarcinoma (PDAC) cells in 12 well plates were treated with increasing doses of mitochondria-targeted ubiquinone (MitoQ), CoQ10, and triphenyl-phosphonium (TPP) for 48 h prior to determining cell viability by crystal violet staining. CoQ10 is the functional moiety of MitoQ and TPP is the vehicle moiety. 462 and 670 denote MCW462 and MCW670 cell lines, respectively; B Summary of the half maximal inhibitory concentration values determined for different PDAC cells treated and analyzed as described; C: MCW462 cells in organoid cultures were treated with increasing doses of MitoQ, CoQ10, and TPP for 48 h prior to determining cell viability by Sytox Green assays. Data (mean ± SEM, *N* ≥ 3) are expressed as the percentage of untreated controls.TPP: Triphenyl-phosphonium; MitoQ: Mitochondria-targeted ubiquinone; IC50: Half maximal inhibitory concentration.



**Figure 2 Mitochondria-targeted ubiquinone can induce caspase-dependent apoptosis in pancreatic adenocarcinoma cells.** A: Apoptosis analysis of cells treated with mitochondria-targeted ubiquinone (MitoQ), with or without Carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone, for 24 h. CoQ10 is the functional moiety of MitoQ and triphenyl-phosphonium is the vehicle moiety. Gemcitabine is the positive control for apoptosis induction. Data (mean ± SEM, *N* ≥ 3) are expressed as the percentage of untreated controls. One-way ANOVA with Bonferroni post-tests; B: Western blot analysis of total lysates of cells treated as described. β-actin is the control for equal amounts of protein loading. a*P* < 0.05. c*P* < 0.001. MitoQ: Mitochondria-targeted ubiquinone; TPP: Triphenyl-phosphonium.



**Figure 3 Erlotinib can increase mitochondrial membrane potential in pancreatic adenocarcinoma cells.** A: Cells were treated with increasing concentrations of erlotinib for 2 d prior to staining with tetramethyl-rhodamine methyl ester (TMRM). Cellular TMRM retention was analyzed by flow cytometry measuring yellow fluorescence; B: Mean fluorescence intensities of TMRM-stained cells quantified by FCS Express software. Data are mean ± SEM (*n* ≥ 3). One-way ANOVA with Bonferroni post-tests; C: Cells pretreated with erlotinib for 48 h were treated with 2 μM mitochondria-targeted carboxy-proxyl (MitoCP) for 1 h. Mitochondrial extracts of these cells were analyzed by Western blotting to detect the formation of MitoCP adducts using the antibody specific to the triphenyl-phosphonium moiety of MitoCP. Total proteins in the extracts were visualized in the stain-free gel as the control for equal protein loading. c*P* < 0.001. MitoCP: Mitochondria-targeted carboxy-proxyl; TPP: Triphenyl-phosphonium.



**Figure 4 Erlotinib can synergize with mitochondria-targeted ubiquinone to suppress the viability of pancreatic adenocarcinoma cells.** A: Cells, pretreated with different concentrations of erlotinib, were treated with different doses of mitochondria-targeted ubiquinone (MitoQ) for 48 h prior to crystal violet viability assay. Data (mean ± SEM, *N* ≥ 3) are expressed as the percentage of untreated controls; B: SynergyFinder plotting of the viability data. The ZIP (zero interaction potency) scores are indicated for the most synergistic areas; C: Western blot analysis of PANC-1 cells maintained in the human plasma-like medium with 1% O2. β-actin is the control for equal protein loading; D: PANC-1 cells pretreated with erlotinib for 24 h were treated with MitoQ for 48 h in the human plasma-like medium with 1% O2 prior to crystal violet viability assay. Data (mean ± SEM, *N* ≥ 3) are expressed as the percentage of untreated controls; E: SynergyFinder plotting of the viability data. The ZIP score is indicated for the most synergistic area. a*P* < 0.05. b*P* < 0.005. c*P* < 0.001, Two-way ANOVA with Bonferroni post-tests. MitoQ: Mitochondria-targeted ubiquinone.



**Figure 5 An erlotinib and mitochondria-targeted ubiquinone combination effectively suppresses PANC-1 xenografts in mice.** A: Treatment schedule. Detailed information is provided in Materials and Method; B: Changes in tumor size (mean ± SEM, *N* = 7). Two-way ANOVA with Bonferroni post-tests; C: Images of tumors collected at the end of treatment; D: Weights of tumors; E: Body weight changes (mean ± SEM, *N* = 7) monitored during the treatment. a*P* < 0.05. b*P* < 0.005. MitoQ: Mitochondria-targeted ubiquinone.